Serax Drug: A Clinician’s Guide to Oxazepam, Its Uses in Anxiety and Alcohol Withdrawal, Why It Is Preferred in Elderly and Liver-Impaired Patients, Side Effects, and Dependence Risks
What the Serax drug is, how oxazepam works as an intermediate-acting benzodiazepine, why its glucuronide metabolism makes it useful in elderly patients and those with liver disease, the typical doses for anxiety symptoms and alcohol withdrawal, the side effects and withdrawal pattern, and what to do when sedative use has become more than occasional.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.
Serax is the brand name for oxazepam, an intermediate-acting benzodiazepine first approved by the FDA in 1965 and still used in clinical practice for the treatment of anxiety symptoms, alcohol withdrawal management, and short-term insomnia. The drug has a half-life of 4 to 15 hours in adults and is metabolised by glucuronide conjugation rather than by hepatic cytochrome P450 enzymes, which makes it particularly useful in elderly patients, those with liver disease, and those on multiple medications that affect liver metabolism. The medication has no active metabolites, which contrasts with diazepam and chlordiazepoxide and produces a more predictable pharmacological profile. Typical adult doses for anxiety symptoms are 10 to 15 mg three or four times daily, with the maximum daily dose of 120 mg. For alcohol withdrawal, dosing of 15 to 30 mg four times daily is commonly used, particularly in patients with significant liver disease. Common side effects include drowsiness, dizziness, ataxia, and the typical benzodiazepine cognitive effects. The medication is a Schedule IV controlled substance with abuse potential and dependence risk with chronic daily use beyond two to four weeks. Treatment of problematic oxazepam use involves a structured taper, treatment of any underlying anxiety, and integrated care for any co-occurring alcohol use disorder or other substance use.
What Serax is and its history
Serax is the brand name for oxazepam, an intermediate-acting benzodiazepine first synthesised in 1961 and approved by the FDA in 1965 for the treatment of anxiety and alcohol withdrawal. The medication is a metabolite of diazepam in the human body and was developed when researchers realised that some of the clinically useful effects of diazepam came from this metabolite rather than from the parent compound. The synthesised oxazepam product avoided the long pharmacological tail of diazepam and its active metabolites, producing a more predictable benzodiazepine with shorter duration of action.
The drug is available in 10 mg, 15 mg, and 30 mg capsules and tablets. Generic oxazepam is widely available and has largely displaced the branded Serax product in current prescribing. The medication is included in the World Health Organization Model List of Essential Medicines for the management of alcohol withdrawal and anxiety disorders, particularly in patients where the glucuronide metabolism makes it preferable to longer-acting benzodiazepines.
Oxazepam works in the body and brain at the gamma-aminobutyric acid type A receptor like other benzodiazepines, enhancing inhibitory neurotransmission to produce anxiolysis, sedation, anticonvulsant activity, and skeletal muscle relaxation. The medication has lower lipid solubility than diazepam, which means slower brain penetration and slower onset of action when given orally (1 to 3 hours to peak effect) compared to the faster-acting benzodiazepines. The slower onset is sometimes a disadvantage for acute anxiety where rapid effect is desired, but it is an advantage for sustained therapy where the slower onset reduces the abuse liability associated with rapid-onset agents like alprazolam.
The pharmacokinetic profile of oxazepam is distinguished by its metabolism through glucuronide conjugation rather than through the hepatic cytochrome P450 enzymes that metabolise most other benzodiazepines. The glucuronidation pathway is preserved in older adults whose CYP450 enzymes have declined and in patients with significant hepatic dysfunction whose CYP450 metabolism is impaired. This makes oxazepam one of the safer benzodiazepines in these vulnerable populations, alongside lorazepam (Ativan) and temazepam (Restoril) which share the same metabolic pathway.
Clinical uses of Serax
The most common clinical use of oxazepam in current practice is the management of anxiety symptoms in adult patients, particularly in older adults and those with liver disease where the glucuronide metabolism provides safety advantages. Typical adult dosing for anxiety is 10 to 15 mg three or four times daily, titrated to the lowest effective dose. The maximum recommended daily dose is 120 mg, though most patients respond at 30 to 60 mg per day. Like other benzodiazepines, oxazepam for anxiety should be limited to short-term use of 2 to 4 weeks because of dependence development with longer therapy.
Alcohol withdrawal management is the second most common indication. The treatment alcohol withdrawal protocols using oxazepam are appropriate for patients with significant liver disease where chlordiazepoxide or diazepam would accumulate dangerously, for older patients where the long-acting benzodiazepines produce excessive sedation, and for patients with concurrent medications that affect hepatic metabolism. Typical alcohol withdrawal dosing is 15 to 30 mg every 4 to 6 hours during the first 24 to 72 hours, then taper over 5 to 10 days. The shorter half-life of oxazepam compared to chlordiazepoxide means more frequent dosing is required, and the taper trajectory is slightly less smooth, but the safety profile in liver disease makes the trade-off worthwhile.
Short-term insomnia treatment is the third indication for oxazepam, though the medication has largely been displaced for this purpose by the z-drugs (zolpidem, eszopiclone, zaleplon), low-dose doxepin, and other newer sleep medications. Oxazepam 15 to 30 mg at bedtime can produce useful sleep effect, but the morning grogginess and the dependence risk with regular nightly use have made other agents preferable for routine insomnia management. The medication may still be appropriate for patients with severe anxiety-related insomnia where the anxiolytic effect during the day complements the sleep effect at night.
Oxazepam is sometimes used for procedural sedation in patients who cannot tolerate other benzodiazepines, for muscle spasm that has not responded to non-benzodiazepine muscle relaxers, and for the management of restless legs syndrome that has not responded to first-line therapy. These indications are off-label and less common than the anxiety and alcohol withdrawal uses, and the medication should generally not be the first choice for these conditions.
Why oxazepam is preferred in elderly and liver-impaired patients
The pharmacological advantage of oxazepam in special populations comes from its metabolism through glucuronide conjugation in the liver. Glucuronidation is a phase II metabolic reaction that conjugates the parent drug with glucuronic acid, producing an inactive metabolite that is excreted in urine. Unlike the phase I oxidation reactions performed by the cytochrome P450 enzyme system, glucuronidation is relatively preserved in older adults and in patients with significant hepatic dysfunction. This means that oxazepam pharmacokinetics are less affected by age and liver disease than those of most other benzodiazepines.
Patients with cirrhosis, alcoholic liver disease, hepatitis, or other significant hepatic impairment show essentially preserved oxazepam metabolism with only modest extension of half-life. Patients on the same dose of diazepam or chlordiazepoxide would experience dramatic accumulation of the parent drug and its active metabolites, producing prolonged sedation, cognitive impairment, and potential respiratory depression. The choice of oxazepam over the longer-acting benzodiazepines in liver disease is a fundamental principle of safe benzodiazepine prescribing in this population.
Elderly patients (over 65 years) have similarly preserved oxazepam metabolism compared to their reduced CYP450 metabolism. Standard adult doses of oxazepam may need only modest reduction (10 to 25 percent) in older patients, while standard doses of diazepam, chlordiazepoxide, or alprazolam may need 50 percent reduction or substitution with a different agent. The American Geriatrics Society Beers Criteria still recommend avoiding all benzodiazepines in older adults when possible, but when a benzodiazepine is necessary, oxazepam and lorazepam are the preferred choices.
Patients on multiple medications that affect CYP450 enzymes also benefit from the oxazepam choice. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice) significantly elevate levels of CYP3A4-metabolised benzodiazepines but have minimal effect on oxazepam. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce levels of CYP3A4-metabolised benzodiazepines but again have minimal effect on oxazepam. Patients on multiple medications with significant CYP450 interactions are often best managed with oxazepam if a benzodiazepine is needed.
Side effects of Serax
The side effects of oxazepam are typical of the benzodiazepine class and include drowsiness, dizziness, ataxia and coordination problems, slurred speech, blurred vision, dry mouth, mild gastrointestinal upset, and reduced libido. Most patients tolerate the medication well at therapeutic doses, and many of the side effects diminish with tolerance over the first one to two weeks of regular use. The cognitive effects (reduced concentration, slowed processing, memory impairment) are dose-related and persist for the duration of use; they are often more apparent to family members and colleagues than to the patient themselves.
Specific common side effects that warrant attention include orthostatic hypotension (particularly in older patients), increased fall risk, daytime drowsiness that may impair driving and operational function, paradoxical reactions with agitation or aggression (more common in children, older adults, and patients with traumatic brain injury or developmental disability), and reduced sexual function. Patients should be told that the medication will impair their driving for at least the first several days of treatment and possibly throughout, and that the impairment is often greater than the patient subjectively appreciates.
Less common but more serious adverse effects include allergic reactions, jaundice and hepatic dysfunction (rare given the glucuronide metabolism), leukopenia, paradoxical seizures in patients with underlying epilepsy, and respiratory depression at high doses or with CNS depressant combinations. Severe overdose can produce profound sedation, hypotension, respiratory depression, and coma; fatal overdose on oxazepam alone is rare and most fatal cases involve combination with alcohol, opioids, or other sedatives.
Drug interactions with oxazepam are fewer than with other benzodiazepines because of the glucuronide metabolism. The most clinically important interactions are with other CNS depressants: alcohol, opioids, other benzodiazepines, z-drugs, barbiturates, and sedating antihistamines all add to the sedation and respiratory depression. The FDA boxed warning on benzodiazepines and opioids combination applies to oxazepam. Drug interactions through CYP450 modulation are essentially absent, which is one of the practical advantages of the medication.
Dependence, tolerance, and withdrawal
Tolerance to the sedative and anxiolytic effects of oxazepam develops with daily use over two to four weeks, similar to other benzodiazepines. The same dose produces less anxiolysis over time, prompting some patients to escalate the dose. Tolerance to the muscle relaxant and anticonvulsant effects develops more slowly. Physical dependence develops with daily use beyond two to four weeks and is essentially universal in patients on the medication for more than three months. The dependence is real and can be substantial, even though the medication is not classically thought of as among the most addictive benzodiazepines.
Withdrawal symptoms after stopping oxazepam in dependent patients begin within 12 to 24 hours of the last dose, peak at 2 to 5 days, and gradually subside over 1 to 4 weeks for short-term users. The shorter half-life means earlier onset of withdrawal compared to longer-acting benzodiazepines. Symptoms include rebound anxiety, insomnia, tremor, sweating, sensitivity to light and sound, gastrointestinal upset, irritability, and in severe cases withdrawal seizures and psychotic symptoms. Long-term users can experience protracted withdrawal lasting months.
A safe taper schedule for oxazepam is appropriate for anyone who has been on the medication for more than a few weeks. The taper typically involves reducing the daily dose by 25 percent every two to four weeks for short-term users, and 5 to 10 percent every two to four weeks for long-term users. The Ashton manual recommends switching from oxazepam to diazepam during the taper (because diazepam has a longer half-life that smooths the trajectory and is available in liquid form for fine adjustment), though oxazepam can be tapered directly using its 10, 15, and 30 mg formulations.
The risk of seizures and severe withdrawal is real for patients on long-term oxazepam, particularly those on doses above 60 mg per day or who have been on the medication for more than a year. These patients should not stop the medication abruptly under any circumstances and should taper under medical supervision with provision for emergency care if severe withdrawal develops. Outpatient taper is appropriate for most patients with stable medical status, but inpatient detoxification is sometimes needed for patients on high doses, with prior failed outpatient tapers, or with significant concurrent alcohol or other substance use.
Comparison with other benzodiazepines
Oxazepam sits in the middle of the benzodiazepine class in terms of half-life and potency. The half-life of 4 to 15 hours is shorter than diazepam (20 to 100 hours including metabolites) and chlordiazepoxide (24 to 48 hours including metabolites) but longer than alprazolam (11 to 12 hours, with much shorter clinically effective duration) and similar to lorazepam (10 to 20 hours). The medication has no active metabolites, which distinguishes it from diazepam and chlordiazepoxide whose metabolites extend the effective duration. The lack of active metabolites and the glucuronide metabolism together make oxazepam predictable in its onset, duration, and offset.
| Benzodiazepine | Half-life | Active metabolites | Metabolism | Notable use |
|---|---|---|---|---|
| Oxazepam (Serax) | 4-15 hr | No | Glucuronidation | Anxiety, alcohol withdrawal in liver disease/elderly |
| Lorazepam (Ativan) | 10-20 hr | No | Glucuronidation | Status epilepticus, anxiety in liver disease/elderly |
| Temazepam (Restoril) | 8-15 hr | No | Glucuronidation | Insomnia |
| Alprazolam (Xanax) | 11-12 hr | No | CYP3A4 | Panic disorder, anxiety |
| Diazepam (Valium) | 20-100 hr | Yes (nordiazepam, oxazepam) | CYP3A4/2C19 | Anxiety, alcohol withdrawal, seizures |
| Chlordiazepoxide (Librium) | 24-48 hr | Yes | CYP3A4 | Alcohol withdrawal, anxiety |
The clinical choice between oxazepam and the alternatives depends on the indication, the patient’s age and medical comorbidities, and the duration of treatment intended. For elderly patients and those with liver disease, oxazepam (or lorazepam) is preferred over the longer-acting CYP450-metabolised agents. For acute anxiety where rapid effect is needed, alprazolam may be preferred despite the higher abuse liability. For alcohol withdrawal in patients with normal liver function, chlordiazepoxide is commonly used because of the smoother taper trajectory. The selection should be individualised and reconsidered if the initial choice is not producing the expected outcomes.
Abuse potential and addiction risk
Oxazepam is a Schedule IV controlled substance in the United States and is recognised as having abuse potential, though it is generally considered to have lower abuse liability than the rapid-onset benzodiazepines like alprazolam. The slower onset of effect (1 to 3 hours to peak) reduces the reinforcing properties of the medication and makes it less appealing to recreational users. The intermediate duration of action also reduces the inter-dose withdrawal that drives compulsive use of shorter-acting agents. These properties have made oxazepam somewhat less of a focus in the broader prescription benzodiazepine abuse crisis compared to alprazolam, clonazepam, and lorazepam.
Despite the lower relative abuse potential, oxazepam can be misused and abused. Patterns of misuse include taking higher doses than prescribed, seeking prescriptions from multiple physicians, using the medication to manage symptoms outside the original indication, and combining with other substances to enhance effects. The risk of misuse is highest in patients with prior substance use disorders, particularly alcohol or other sedative-hypnotic use disorders, and in patients with significant psychiatric comorbidity that has not been adequately treated.
Patients who develop opioid use disorder, alcohol use disorder, or other substance use disorder while on long-term oxazepam therapy are at substantially elevated risk of overdose because of the cumulative CNS depressant effect. The combination with alcohol is particularly dangerous and is one of the leading patterns in benzodiazepine-related overdose deaths. Honest disclosure of all substance use to the prescriber is essential, and integrated treatment of any co-occurring substance use disorder produces better outcomes than treating either condition in isolation.
The treatment of problematic oxazepam use involves a structured taper, treatment of the underlying anxiety or other condition that drove the original prescription, and addiction medicine assessment for any co-occurring substance use disorder. Cognitive behavioural therapy, motivational interviewing, and mutual-help groups can support the work of the taper. For patients with significant polysubstance use or with severe psychiatric comorbidity, residential treatment may be appropriate. The Phuket Island Rehab residential program provides this kind of integrated care for international patients seeking confidential recovery.
When sedative use and drinking have become more than occasional
For readers who have been on Serax or generic oxazepam for months or years and recognise the dependence pattern, or who are concerned about how the medication is interacting with their drinking, the conversation with the prescriber is the appropriate starting point. Many patients on long-term benzodiazepine therapy have continued the medication well past the original indication, often because they have not been offered alternatives or because the difficulty of the taper has not been adequately addressed. The conversation can include reassessment of the indication, evaluation for alternatives (cognitive behavioural therapy for anxiety, SSRIs for chronic anxiety, addiction medicine assessment if substance use is part of the picture), and planning for a structured taper if appropriate.
Heavy drinking is one of the most common substance use patterns that coexists with long-term benzodiazepine use, often because the two substances have cross-tolerance at the GABA-A receptor and produce reinforcing effects together. The combination is particularly dangerous because of the cumulative respiratory depression risk and because the increasing doses of one substance can produce withdrawal from the other in complicated patterns. The patient who is taking oxazepam and drinking heavily often does not see either substance as a problem because each appears to be a manageable part of their daily routine.
Alcohol use disorder, the clinical term for problematic alcohol use, is defined by the DSM-5 criteria including drinking more than intended, unsuccessful efforts to cut down, craving, tolerance, withdrawal, and continued use despite consequences. Many patients on long-term oxazepam also meet AUD criteria. Phuket Island Rehab provides residential addiction medicine treatment for benzodiazepine dependence, alcohol use disorder, and dual diagnosis cases that include co-occurring anxiety, depression, or other mental health conditions.
Summary
Serax (oxazepam) is an intermediate-acting benzodiazepine used for the treatment of anxiety symptoms, alcohol withdrawal, and short-term insomnia. The medication has a half-life of 4 to 15 hours, no active metabolites, and is metabolised by glucuronide conjugation rather than by hepatic cytochrome P450 enzymes. The glucuronide metabolism makes oxazepam particularly useful in elderly patients, those with liver disease, and those on multiple medications affecting CYP450 enzymes. Common side effects include drowsiness, dizziness, ataxia, and the typical benzodiazepine cognitive effects. The medication is a Schedule IV controlled substance with abuse potential and dependence risk with chronic daily use beyond two to four weeks. Withdrawal symptoms after stopping include rebound anxiety, insomnia, tremor, and in severe cases seizures. A structured taper is appropriate for anyone who has been on the medication for more than a few weeks. As Dr. Ponlawat Pitsuwan summarises, “Oxazepam is one of the safer benzodiazepines for patients who genuinely need short-term treatment of anxiety or alcohol withdrawal, particularly in older adults and those with liver disease. The same medication used for years for chronic anxiety becomes a different problem, and the patient deserves careful taper combined with proper treatment of the underlying condition.”
Frequently asked questions
What is the Serax drug used for?
Serax (oxazepam) is most commonly used for the treatment of anxiety symptoms and for the management of alcohol withdrawal, particularly in elderly patients and those with liver disease where its glucuronide metabolism provides safety advantages. It is also used for short-term insomnia and occasionally for muscle spasm and other off-label indications.
How long does Serax stay in your system?
Oxazepam has a half-life of 4 to 15 hours and is detectable in urine for 3 to 7 days after the last dose in occasional users, and for 1 to 2 weeks in chronic users. The drug has no active metabolites, which produces a more predictable clearance profile than benzodiazepines with long-acting active metabolites.
Is Serax safer than xanax?
Both are Schedule IV controlled substances and both carry dependence and abuse risks. Oxazepam has somewhat lower abuse liability than alprazolam because of its slower onset of effect, and is preferred in elderly patients and those with liver disease because of its glucuronide metabolism. Alprazolam is more effective for acute panic attacks because of its faster onset. The ‘safer’ question depends on the specific clinical situation and patient.
How does Serax compare to Ativan?
Both oxazepam (Serax) and lorazepam (Ativan) are intermediate-acting benzodiazepines without active metabolites, both metabolised by glucuronide conjugation, and both preferred in elderly patients and those with liver disease. The two medications are clinically interchangeable in most situations. Lorazepam has slightly faster onset and is available in injectable form for status epilepticus, while oxazepam has slightly longer duration of action.
Can I take Serax with alcohol?
No. The combination of oxazepam and alcohol substantially increases sedation, respiratory depression risk, and accidental injury risk. Both substances enhance GABA-A receptor function and the combined effect is more than additive. Patients on Serax should avoid alcohol entirely, and any drinking that is occurring should be honestly disclosed to the prescriber.
How do I stop taking Serax safely?
A structured taper under medical supervision is essential for anyone who has been taking oxazepam regularly for more than a few weeks. The taper typically involves dose reductions of 25 percent every two to four weeks for short-term users, and 5 to 10 percent every two to four weeks for long-term users. Stopping abruptly after sustained use can produce withdrawal seizures and severe rebound symptoms.
Sources
- U.S. Food and Drug Administration (FDA). Oxazepam prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015539s055lbl.pdf
- Ashton CH. Benzodiazepines: How they work and how to withdraw (The Ashton Manual). 2002. https://www.benzo.org.uk/manual/
- American Geriatrics Society Beers Criteria Update Expert Panel. 2023 AGS Beers Criteria. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18372
- American Society of Addiction Medicine (ASAM). Clinical Practice Guideline on Alcohol Withdrawal Management. 2020. https://www.asam.org/quality-care/clinical-guidelines/alcohol-withdrawal-management-guideline
- National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. https://www.nice.org.uk/guidance/cg113
- World Health Organization (WHO). Model List of Essential Medicines. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines
- Substance Abuse and Mental Health Services Administration (SAMHSA). National helpline. https://www.samhsa.gov/find-help/national-helpline
serax drug, serax, oxazepam, benzodiazepine, intermediate-acting benzodiazepine, FDA, GABA-A receptor, GABA, anxiolysis, sedation, anticonvulsant, anxiety, anxiety symptoms, generalised anxiety disorder, alcohol withdrawal, alcohol withdrawal syndrome, insomnia, panic disorder, side, side effects, oxazepam, use, withdrawal, withdrawal symptoms, anxiety, symptoms, medication, alcohol, drugs, dose, risk, medical, take, treatment, health, hospital, dependence, tolerance, addiction, abuse, abuse potential, Schedule IV controlled substance, glucuronidation, glucuronide conjugation, phase II metabolism, cytochrome P450, CYP3A4, CYP2C19, no active metabolites, lorazepam, Ativan, temazepam, Restoril, diazepam, Valium, alprazolam, Xanax, chlordiazepoxide, Librium, half-life, elimination half-life, peak effect, drowsiness, dizziness, ataxia, paradoxical reaction, hypotension, respiratory depression, overdose, hepatic impairment, liver disease, cirrhosis, alcoholic liver disease, hepatitis, elderly, older adults, geriatric, polypharmacy, AGS Beers Criteria, Ashton manual, taper, structured taper, FDA boxed warning, opioid, alcohol use disorder, AUD, DSM-5, dual diagnosis, NICE, WHO, ASAM, SAMHSA, NHS 111, Phuket Island Rehab, addiction medicine, residential rehab.